PharVision Advisers’s Power Solutions International PSIX Stock Holding History

PharVision Advisers’s Portfolio PSIX Stock Details PSIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,843	Closed	-$220K	–	689
2025 Q4	$220K	Buy	+3,843	New	+$274K	0.11%	483

Other funds holding PSIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Situational Awareness San Francisco, California $13.7B AUM 334.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's PSIX Position: Q1 2026 in Review

PharVision Advisers sold out of Power Solutions International (PSIX) in Q1 2026, closing a stake of 3,843 shares — an estimated $220K sold.

PharVision Advisers first reported a position in PSIX in Q4 2025 and held it in 1 quarter. The position peaked at $220K in Q4 2025. 201 funds tracked by Wall St. Rank hold PSIX as of Q1 2026.

PharVision Advisers reported no remaining Power Solutions International position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,843 Power Solutions International shares in Q1 2026, an estimated $220K.
PharVision Advisers first reported a position in Power Solutions International in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Power Solutions International position peaked at $220K in Q4 2025.
201 funds tracked by Wall St. Rank held Power Solutions International as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.